Home » Sanofi Pasteur Chooses Intercim for Mastering Manufacturing Processes
Sanofi Pasteur Chooses Intercim for Mastering Manufacturing Processes
Intercim, announces that Sanofi Pasteur, the vaccines division of the Sanofi-aventis Group, is accelerating the use of Pertinence Suite, Manufacturing Operations Management (MOM) software solution, within the European and North American sites of the worldwide leader of vaccines.
Vaccines come from complex biological processes. The understanding of such manufacturing process is one of the key elements to master products quality and production units performances. Since 2003, Sanofi Pasteur has used the Pertinence Suite solution to better understand, improve reliability and optimize industrial processes.
Rene Labatut, Vice President Manufacturing of Sanofi Pasteur explains: "Manufacturing, and guaranteeing the highest level of quality and safety for the patient, and the optimum performances for the company, are key objectives of process understanding. It is also a corporate challenge in the current competitive environment. The use of Pertinence Suite for understanding mechanisms which drive our complex processes is an asset that provides answers to this double requirement in an efficient manner".
The new deployment of Pertinence Suite demonstrates the willingness to implement in a very operational manner the approach promoted by the regulatory bodies through the ICH Quality by Design (QbD). This approach aims at mastering manufacturing processes and efficiently, while sharing with the authorities the understanding of the mechanisms which drive products critical quality attributes.
Yann d'Aramon, Director Europe of Intercim adds: "We are very pleased of Sanofi Pasteur decision to spread the use of our solutions through their plants around the world. With our solutions, Sanofi Pasteur can identify and set up in real-time, parameters influencing the product quality, and moving forward, better control process variability. This is a recurrent challenge for the pharmaceutical industry which needs to consistently deliver vaccines on time, with a perfect traceability."
Intercim has a 27-year history of helping advanced and highly regulated manufacturers reach their business goals through best in class software solutions. Early 2009, Dassault Systemes a world leader in 3D and Product Lifecycle Management took a minority position in Intercim. Both companies consider critical that information exchange and collaboration between engineering, manufacturing and the supply network be handled in real-time. For the first time, the combination of Intercim's software capabilities with the virtual experience provided by Dassault Systemes' solutions allows this type of mission-critical collaboration and knowledge sharing.
Intercim works mainly for advanced and highly regulated industries and with industry-leading customers such as Boeing, Sanofi Pasteur, Ball Aerospace, BMW, and Honeywell.
Novo Acquires Xellia Pharmaceuticals for $700 MillionFrom PharmaTimes Online
Novo A/S has acquired Xellia Pharmaceuticals of Norway
Royalty Increases Bid as Elan Unveils AcquisitionsFrom PharmaTimes Online
Royalty Pharma has resurfaced to raise its bid to acquire the Irish drugmaker Elan
New Asthma Drug Offers Hope for PatientsFrom Forbes
An experimental asthma drug could give new hope to patients for whom existing medicines are not enough
Syrian Pharma Production Nearly Halted by WarFrom AFP
A shortage of foreign currency has brought production to a near halt in Syria
Camfil APC Opens Manufacturing Plant in the UKFrom Camfil
Camfil announced the grand opening of its new 40,000-sq.-ft. facility
Actavis Acquiring Warner Chilcott for $8.5BFrom AP
Actavis to buy Warner Chilcott in an all-stock transaction
Northwest Analytics Launches Next Generation Enterprise Manufacturing Intelligence SolutionFrom Northwest Analytics
NWA Focus EMI Delivers Real Time Process Intelligence and Unique Accelerating Modules - a Shared Knowledge Base and Manufacturing-Centric Collaboration
Innovative Clinical Development Partnership Announced By Quintiles and Merck SeronoFrom MarketWatch.com
Agreement creates unique strategic collaboration for development and clinical trial execution
$15 Billion Myland Offer Rejected By ActavisFrom Bloomberg.com
Actavis has rejected drugmaker Mylan Inc's cash-and-stock offer for $15 billion. They have decided to continue talks to take over Warner Chilcott Plc instead, sources have said.
Rapid Micro Biosystems Offers Workshops at New European Headquarters in MunichFrom Rapid Micro Biosystems
Company hosts hands-on demonstrations of its Growth Direct System
- All news »